Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Leases (2019 - 2025)

Karyopharm Therapeutics' Current Leases history spans 7 years, with the latest figure at $969000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 121.23% year-over-year to $969000.0; the TTM value through Dec 2025 reached $969000.0, up 121.23%, while the annual FY2025 figure was $969000.0, 121.23% up from the prior year.
  • Current Leases reached $969000.0 in Q4 2025 per KPTI's latest filing, up from $922000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.7 million in Q3 2024 to a low of $438000.0 in Q4 2024.
  • Average Current Leases over 5 years is $2.4 million, with a median of $2.5 million recorded in 2022.
  • Peak YoY movement for Current Leases: crashed 86.76% in 2024, then skyrocketed 121.23% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.3 million in 2021, then rose by 24.01% to $2.9 million in 2022, then increased by 15.18% to $3.3 million in 2023, then plummeted by 86.76% to $438000.0 in 2024, then skyrocketed by 121.23% to $969000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Current Leases are $969000.0 (Q4 2025), $922000.0 (Q3 2025), and $1.4 million (Q2 2025).